There are a number of public health interventions that are important. To prevent HAV and HEV, best practice in hygiene, food handling, and environmental health are required. For HBV, HCV and HDV prevention screening and other forms of blood safety, health care injection and procedure safety, infection control, safe sex practices, and harm reduction for people who inject drugs. Medications for the treatment of HBV and HCV are now more than 90% effective, but remain very expensive. 5 The WHO estimated that unsafe injections decreased from 39% in 2000 to 5% in 2010 worldwide, but continued emphasis on best practice must continue. 1 The public health efforts of China to combat hepatitis have been very successful. It is estimated that in China, 28 million people were prevented from acquiring chronic HBV infection and 5 million people prevented from dying of complications related to HBV between 1992 and 2014. 9 This is a remarkable effort in prevention.
HCV was first discovered in 1986 and chronic HCV infection is estimated to be present in 71 million persons worldwide. HCV infection is usually asymptomatic in the early stages, but one third of HCV carriers develop cirrhosis and many progress to hepatocellular carcinoma. Around 6% eventually die from their HCV infection. 10 The cost of treatment of HCV, which is 90% effective with the new direct-acting antiviral drugs (such as sofosbuvir), can be very expensive at up to 1000 times (yes this is not a misprint) the actual cost of production. 10 While this may be a boon to hedge fund managers, it is a travesty of the egalitarian aims of public health. Costs vary considerably from country to country and fortunately in some developing countries can be as low as 1% of the costs in the United States. But, what is really needed is an effective and cheap vaccine.
There are numerous other causes of hepatitis due to the toxicity from alcohol, aflatoxins (from fungi growing on food), and some types of herbs and ferns. An emerging problem is the growing use of herbal medicines, some of which can result in a form of toxic hepatitis and liver failure. 11 The experience of Qidong in Jiangsu Province is a very informative case study on the value of public health surveillance in understanding the natural history and epidemiology of a disease and public health threat. 12 The Qidong Cancer registry tracked the 60% decline in deaths from hepatocellular cancer, a complication of chronic hepatitis, as aflatoxin contamination of food was reduced. This was mainly due to a change from a maize-based diet to rice. (Maize is more prone to moisture damage and the development of mould.) Climate change in our region is a major concern and increases in moisture and higher temperatures will increase the risk of aflatoxininduced liver damage.
On World Children's Day, 1 June 2017, the World Hepatitis Alliance issued a plea for governments to work toward the elimination of HBV by vaccinating all infants at birth. They estimate that in the Southeast Asia region, only 34% receive the birth dose vaccine and in the African region as few as 10% receive the birth dose. 13 Hepatitis is a major public health issue in our region and is an important component of the public health curriculum. During Hepatitis month, it is important that APACPH (Asia-Pacific Academic Consortium for Public Health) members emphasize to their students the continuing efforts that are needed to control this group of diseases. Over the years, the Asia Pacific Journal of Public Health has recognized the importance of hepatitis and we have published 115 articles on the topic, including 98 research articles. We would welcome new submissions to track the progress in our region.
The 49th APACPH conference will be held on the Yonsei University campus in Seoul in August 2017. Your editors will be there and we are always interested in meeting our authors and readers. Once again, we will be offering a workshop on writing papers.
